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Abstract
Background: Acute herpes zoster is a prevalent condition. One of its major symptoms is pain,
which can highly influence patient's quality of life. Pain therapy is limited. Acupuncture is supposed
to soften neuropathic pain conditions and might therefore act as a therapeutic alternative.
Objective of the present study is to investigate whether a 4 week semi-standardised acupuncture
is non-inferior to sham laser acupuncture and the anticonvulsive drug gabapentine in the treatment
of pain associated with herpes zoster.
Methods/Design: Three-armed, randomised, placebo-controlled trial with a total follow-up time
of 6 months. Up to estimated 336 patients (interim analyses) with acute herpes zoster pain (VAS
> 30 mm) will be randomised to one of three groups (a) semi-standardised acupuncture (168
patients); (b) gabapentine with individualised dosage between 900–3600 mg/d (84 patients); (c)
sham laser acupuncture. Intervention takes place over 4 weeks, all patients will receive analgesic
therapy (non-opioid analgesics: metamizol or paracetamol and opioids: tramadol or morphine).
Therapy phase includes 4 weeks in which group (a) and (c) consist of 12 sessions per patient, (b)
visits depend on patients needs. Main outcome measure is to assess the alteration of pain intensity
before and 1 week after treatment sessions (visual analogue scale VAS 0–100 mm). Secondary
outcome measure are: alteration of pain intensity and frequency of pain attacks; alteration of
different aspects of pain evaluated by standardised pain questionnaires (NPI, PDI, SES); effects on
quality of life (SF 36); analgesic demand; alteration of sensoric perception by systematic quantitative
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sensory testing (QST); incidence of postherpetic neuralgia; side effects and cost effectiveness.
Credibility of treatments will be assessed.
Discussion: This study is the first large-scale randomised placebo controlled trial to evaluate the
efficacy of acupuncture compared to gabapentine and sham treatment and will provide valuable new
information about the clinical and physiological effects of acupuncture and gabapentine in the
treatment of acute herpes zoster pain. The study has been pragmatically designed to ensure that
the study findings can be implemented into clinical practice if acupuncture can be shown to be an
effective treatment strategy in acute herpes zoster pain.
Trial registration: NCT00885586
Background
Herpes zoster is a distinctive syndrome caused by reactiva-
tion of varicella zoster virus (VZV). It is characterized by a
painful, blistering skin eruption following dermatomal
distribution. As cellular immunity to VZV decreases with
age, stress or because of immunosuppression, the virus
reactivates and travels along the sensory nerves to the skin,
causing distinctive prodromal pain followed by eruption
of rash [1]. The diagnosis of herpes zoster is clinically
based on the characteristic appearance of the rash. Only in
clinically unclear cases lesional detection of VZV-DNA by
PCR might be used to confirm the diagnosis.
Herpes zoster can occur at any age but most commonly
affects the elderly population. It is estimated that approx-
imately 1 in 3 people will develop herpes zoster during
their lifetime. The incidence of herpes zoster and the rate
of herpes zoster-associated complications increase with
age [2,3].
Symptoms that herald herpes zoster include pruritus, dys-
esthesia and pain along the distribution of the involved
dermatome. The most distressing symptom is typically
pain and the most feared complication beside CNS or
ocular involvement is postherpetic neuralgia (PHN), the
persistence of pain after rash healing. PHN is defined as
pain persisting more than 3 months after the rash has
resolved [4-6]. In patients aged over 70 years almost half
develop PHN after acute herpes zoster [7]. Both, the acute
pain associated with herpes zoster and the chronic pain of
PHN, have multiple adverse effects on health-related
quality of life. Different types of pain and other sensory
symptoms are found in patients with herpes zoster, and
these vary greatly with respect to their presence, location,
duration, intensity, and quality [8]. These pain conditions
cause substantial interference with physical, emotional,
and social functioning [5,8] and result in increased health
care costs [9].
The development of effective strategies for the prevention
and treatment of pain associated with herpes zoster and
PHN is therefore an unmet public health need [8]. Early
recognition and treatment of herpes zoster can reduce
acute symptoms and may also reduce the occurrence of
PHN [9].
The evidence base supports the oral use of tricyclic antide-
pressants, certain opioids, and gabapentinoids to prevent
or treat PHN [10]. Authors in this meta-analysis were able
to extract an appreciable frequency of minor adverse
events. The most frequently reported adverse events are
dizziness and sedation, thus decreasing patients' daily
quality of life and compliance [10]. In addition, current
opinion is that existing interventions do not completely
prevent or adequately treat all cases of herpes zoster pain
and PHN [10-12].
Acupuncture might figure as an alternate. There is some
evidence, that acupuncture might be favourable in the
treatment of neuropathic pain conditions [13]. In addi-
tion acupuncture is known to be a safe treatment poor in
adverse effects [14]. Though, there are only some smaller
studies about acupuncture treatment in patients with her-
pes zoster [15-19] showing controversial results. Broad
clinical studies are missing.
Aim of the study
The primary objective of the trial presented is to investi-
gate whether a 4 week semi-standardised acupuncture is
non-inferior to the anticonvulsive drug gabapentine and
sham laser acupuncture as placebo control in the treat-
ment of pain associated with herpes zoster in addition to
standardised analgesics. Secondary objectives include
alteration of pain intensity and frequency of pain attacks,
alteration of different aspects of pain evaluated by stand-
ardised pain questionnaires (NPI, PDI, SES), effects on
quality of life (SF 36), analgesic demand, alteration of
sensoric perception, incidence of postherpetic neuralgia,
side effects and cost effectiveness.
Methods/Design
Design
The ACUZoster study is a three-armed, partially blinded
randomised placebo-controlled trial investigating the effi-BMC Complementary and Alternative Medicine 2009, 9:31 http://www.biomedcentral.com/1472-6882/9/31
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cacy of (a) acupuncture versus (b) gabapentine or (c)
sham laser acupuncture in the treatment of pain associ-
ated with acute herpes zoster in addition to a standardised
analgesic regimen respectively (Figure 1). Patients are
blinded regarding acupuncture and sham laser acupunc-
ture treatment. After randomisation, patients in the acu-
puncture and sham laser acupuncture group receive 12
treatment sessions over a period of 4 weeks. In the gabap-
entine group, all patients receive the drug-uptake accord-
ing to a standardised scheme. Appointments with
gabapentine group patients depend on their needs and
might happen up to 12 times in 4 weeks, but at least once
a week. All patients are treated with standard antiviral,
local and basic analgesic regimen. Furthermore patients
can receive analgesic escape medication, so that a suffi-
cient pain therapy is guaranteed. The total follow-up study
period per patient is 6 months. Ethical approval has been
given by the Ethics Committee of the University of
Munich, Munich, Germany (registration 159-08).
Patients
The ACUZoster trial aims to recruit up to a maximum of
336 patients. Recruitment for the trial started in Novem-
ber 2008. For inclusion patients must meet the following
criteria: confirmed diagnosis of acute herpes zoster
(recruitment at the Departments of Dermatology and
Allergology, Ludwig Maximilians Universität and Tech-
nische Universität München, Munich, Germany), pain
intensity > 30 mm on a visual analogue scale (VAS 0–100
mm), standardised antiviral therapy with either brivudin
(125 mg/d p.o.) or aciclovir (3 × 5–10 mg/kg/d KG i.v. or
5 × 800 mg/d p.o.).
Main exclusion criteria are: Patients with insulin-depend-
ent diabetes mellitus or other diseases influencing the
peripheral sensibility (e.g. polyneuropathia, chronic pain
syndromes, cutaneous irritations i.e. burns); patients
under age (< 18 years); non-compliance; pregnancy or lac-
tation; surgery within the last 3 month; severe heart/lung/
kidney disease; diseases influencing the quality of life;
psychiatric diseases (e.g. depression, schizophrenia,
dementia); chronic intake of analgesics, neuroleptics,
antidepressants, corticoids, alpha-agonists; acupuncture,
transdermal electric neurostimulation or other Comple-
mentary and Alternative Medicine treatment within the
last 4 weeks; contraindications according to the summary
of product information against analgesic treatment (i.e.
metamizol, paracetamol, tramadol, morphine) or the
investigational medicinal products (gabapentine, acu-
puncture needles).
Participating physicians
Participating trial physicians form part of the Multidisci-
plinary Pain Centre, Department of Anaesthesiology, Uni-
versity of Munich, Germany. All are experienced in pain
treatment. Their acupuncture training reaches at least the
level of "A-diploma" from one of the major German acu-
puncture societies (140 hours of curricular teaching) such
as more than two years practical skills training at the
Multidisciplinary Pain Centre. All physicians are experi-
enced in working in clinical trials.
Randomized treatment allocation, and sample-size 
estimation
The randomization to one of the three arms of the study
has been carried out by the Institute of Medical Informa-
tion Technology, Biometry and Epidemiology, University
of Munich, Germany (IBE). The investigators established
a computer-based randomisation procedure (Randou-
lette®) which after including the patient to the trial allo-
cates subjects to the respective arms balancing their age
and gender
We conduct a 3-armed study, which shall prove the non-
inferiority of an experimental therapy (acupuncture)
against a reference therapy (gabapentine) by simultane-
ous placebo control (sham laser acupuncture). The sam-
ple size estimation was based on the approach of Pigeot,
Schäfer, and Röhmel [20]. Following assumptions were
made on the basis of a prior study [13].
￿ VAS change under acupuncture treatment: μE = 15
mm
Trial design, time schedule, and outcome parameters of the  ACUZoster study Figure 1
Trial design, time schedule, and outcome parame-
ters of the ACUZoster study. Acupuncture (ACU), 
Gabapentine (GABA), Sham Laser Acupuncture (SLA). Out-
come measures: Main outcome measure: Alteration of Pain 
intensity (VAS); Secondary outcome measure: alteration of 
pain intensity/frequency (evaluated by diary); pain question-
naires (including: NPI, PDI, SES, please refer to Table 3); qual-
ity of life (SF-36) Sensoric perception evaluated through 
qualitative sensory testing (QST); credibility assessment 
according to Vincent; cost effectiveness and safety aspects.
ACU (n = 168)
12 sessions
GABA (n = 84)
900-3600 mg/d
SLA (n = 84)
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Follow-up
Follow-up
Follow-up
Basic 
Therapy
Randomisation
2  : 1 : 1
Time schedule (weeks) 0 4 5 6 26
Outcome measure
VAS
Pain intensity /frequency
Pain questionnaires
Quality of life
Sensoric perception (QST)
Credibility assessment
Cost effectiveness
Safety
x x x                 x x
I----------------------------I
xx x
xx x
xx x
xx
I----------------------------I
I----------------------------IBMC Complementary and Alternative Medicine 2009, 9:31 http://www.biomedcentral.com/1472-6882/9/31
Page 4 of 9
(page number not for citation purposes)
￿ VAS change under gabapentine (reference treat-
ment): μR = 15 mm
￿ VAS change under sham treatment: μP = 5 mm
￿ Noninferiority margin: θ = 50% of the difference
between the reference and the sham treatment (i.e. 5
mm VAS)
￿  σ = 15,6 (estimated standard deviation within
groups)
￿ α = 0,025 (one-sided)
￿ β = 0,2 (power: 80%)
The necessary sample size under these assumptions was
estimated as n = 336, with an optimal allocation of 168
patients to the acupuncture group and 84 patients each to
the reference and placebo group. The dropout rate should
not be higher than 10%.
To allow for early termination, the study was designed to
be assessed in four equally spaced interim analyses and
one final analysis. Therefore, α-levels were adjusted
according to O'Brien-Fleming to maintain the assumed
0,025-level for the overall study analysis [21].
Interim analysis 1 (20% of all patients): 0,00000
Interim analysis 2 (40% of all patients): 0,00039
Interim analysis 3 (60% of all patients): 0,00368
Interim analysis 4 (90% of all patients): 0,01102
Overall study analysis (100% of all patients): 0,02113
Statistical analysis
Establishing noninferiority of the experimental therapy E
(acupuncture) to the reference therapy R (Gabapentin)
requires hierarchical testing of the following hypotheses
using t tests [20]:
In a first step,   is tested using the appropriate alpha
level. Only if   is rejected, the second hypothesis H0 is
tested, using the same alpha level. If H0 is rejected, nonin-
feriority is established. If the first step does not lead to the
rejection of  , noninferiority cannot be established at
this stage of the study.
Interventions
Basic therapy (all groups)
All patients are treated by the attending dermatologists
immediately after diagnosis of herpes zoster with a stand-
ardised antiviral therapy with either brivudin (125 mg/d
p.o.) or aciclovir (3 × 5–10 mg/kg/d KG i.v. or 5 × 800 mg/
d p.o.) as well as a symptomatic therapy of rash with local
antiseptics according to the guidelines of the German Der-
matological Society (Deutsche Dermatologische Gesells-
chaft DDG, [22]).
In addition all patients have the possibility to receive a
standardised analgesic treatment, according to WHO rec-
ommendations: step 1: nonopioid analgesics (Metamizol
4 × 1.0 g p.o. (4 × 40 gtt). Paracetamol 4 × 1.0 g), step 2:
additionally moderate opioids (tramadol, maximum dose
600 mg/d), step 3 recommends use of stronger opioids
(morphine). Escape medication available for step 2 and 3
are tramadol respectively morphine drops. Patients are
not allowed to use other analgesics or analgetic therapies.
Acupuncture treatments (a + c)
Patients in the acupuncture group and the sham laser
group will receive an acupuncture treatment. Acupuncture
treatment is semi-standardised. Obligatory basic points
with and without electrical stimulation have to be chosen.
In addition facultative individual points can be chosen
according to the diagnostic pattern and its corresponding
meridian systems (Table 1). Detailed diagnosis according
to Western and Chinese diagnostic considerations
(including pulse and tongue diagnosis) is assessed. Cho-
sen acupuncture points are recorded.
The treatment strategies for acupuncture were developed
based on a consensus process with experienced acupunc-
ture experts representing members of the faculty of one of
the major German societies for medical acupuncture: Ger-
man Medical Acupuncture Association (Deutsche Ärzteges-
ellschaft für Akupunktur, DÄGfA).
Both treatment groups (needle and sham laser) consist of
12 sessions within 4 weeks (3 sessions/week). Each ses-
sion is supposed to last 20 minutes. Resting time after
both treatments is 20 minutes.
(1) The needle acupuncture technique (a) used in this trial
is performed using expendable needles (Seirin® 0.15 × 20
mm or 0.3 × 30 mm and Asiamed® 0.25 × 40 mm) at
defined acupuncture points and treatment areas. After
needle insertion, the needle is manipulated until the sub-
ject obtains the deqi response (a deep aching or full feel-
ing at the needle). Needle techniques include very point
technique and dry needling. Further manipulation can be
obtained applying an electro acupuncture device (AS
Super 4 Han, schwa-medico, Ehringshausen, Germany).
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(2). Sham laser acupuncture (c) is applied at equivalent
points as needle acupuncture, approaching a non-func-
tioning laser pen which had been deactivated before by
the manufacturer (Handy CW 100, schwa-medico). Only
red light is emitted. For emphasis of the imaginary power
of this sham procedure, visual and acoustic signals are
accompanying the red light emission. Patients are treated
45 sec. without skin contact.
Gabapentine (b)
Patients are treated individually with gabapentine 900
mg/d – 3600 mg/d. According to the recommended
scheme given by the manufacturer (Table 2), the initial
dose of 300 mg/d is (1) gradually augmented up to a daily
dose of 900 mg and can (2) be increased dependent on
the patients needs (maximum dose: 3600 mg/d). When
symptoms release for at least one week, reduction of daily
gabapentine amount is aspired.
Patients are scheduled for re-assessment at least once a
week.
Ethics
The trial has been approved by the Ethics Committee of
the University of Munich such as the national component
authority (Bundesinstitut für Arzneimittel und Medizin-
produkte BfArM). The study protocol is in accordance to
the declaration of Helsinki and the „ICH E6 Guideline for
Good Clinical Practice”. Written informed consent is
obtained from all patients.
Monitoring
The study will be conducted according to common guide-
lines for clinical trials (Declaration of Helsinki ICH-GCP,
Version Seoul 2008, cf. http://www.wma.net/e/policy/
pdf/17c.pdf), including certification by an external audit
according to ICH-GCP at the Institute for Medical Infor-
matics, Biometrics and Epidemiology (IBE), Ludwig-Max-
imilians-University, Munich, Germany. Data protection
such as adequate quality and safety control according to
the guidelines for good clinical practice (CPMP/ICH/135/
95) is assured. Trial registration is EudraCT 2006-004698-
86.
Table 1: Acupuncture Treatment protocol
AcuPoint Traditional Name Indication (acc. to TCM)
Obligatory basic points applied with electrical stimulation
LI 4 He Gu pain; skin diseases; restlessness; inflammation; head affections
LI 11 Qu Chi strengthen the immune system; pain; skin diseases; restlessness; 
inflammations
dependent on the primary diagnostic pattern either
LR 3 Tai Chong headache; psychosomatic symptoms with stress and restlessness; 
muscular tension; spasmolytic
GB 34 Yang Ling Quan pain and tension in muscles and tendons
or
SP 10 Xue Hai immunmodulatoric effect; skin diseases
BL 40 Wei Zhong skin diseases; local burning and heat symptoms
Obligatory basic points (electrical stimulation optional)
Points on the meridian system corresponding to the primary diagnostic pattern (at least 2)
Segmental points (standard segmental points e.g. Huatuo or BL points, as well as Ah Shi points, at least 2)
Local points (at least 4)
Facultative points can be chosen according to diagnosis and/or symptoms
Standard acupuncture points, Ah Shi points, Microsystempoints (e.g. ear), myofascial triggerpointsBMC Complementary and Alternative Medicine 2009, 9:31 http://www.biomedcentral.com/1472-6882/9/31
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Blinding
Patients are blinded and told they would receive either
acupuncture or laser acupuncture or a medical treatment.
They are told that one treatment only could be less effec-
tive than a series of applications. Instead of true laser acu-
puncture, a sham laser acupuncture treatment is
performed. In addition, examiners providing the sensory
testing and that are involved with the data management
are blinded about patients' treatment.
Outcome measures
Main outcome measure
Alteration of pain intensity before and 1 week after treat-
ment sessions (visual analogue scale VAS 0–100 mm, with
0 being no pain and 100 being the maximum imaginable
pain.
Secondary outcome measure
Alteration of pain intensity and frequency of pain attacks,
analgesic demand, evaluated by diary; alteration of differ-
ent aspects of pain evaluated by standardised pain ques-
tionnaires (NPI, PDI, SES); effects on quality of life (SF
36), alteration of sensoric perception by systematic quan-
titative sensory testing (QST); incidence of postherpetic
neuralgia; side effects and cost effectiveness. QST meas-
urements are taken before and 1 week and 6 months after
treatment. For detailed information please refer to Table
3.
Credibility assessment
Expectations about outcome are the main modifying var-
iables of the placebo effect according to Strauss-Blasche
Table 2: Gabapentin Scheme
Day Time 8°° a.m. 14°° a.m. 22°° p.m.
Day 1 - - 300 mg
Day 2 300 mg - 300 mg
Day 3 300 mg 300 mg 300 mg
Increase depends on patients needs
Day n 300 mg 300 mg 600 mg
Day n + 1 600 mg 300 mg 600 mg
Day n + 2 600 mg 600 mg 600 mg
...
Maximum dose 1200 mg 1200 mg 1200 mg
Table 2 is demonstrating the gabapentine intake scheme to reach the 
wanted therapeutic dosage. n is in sequence of the days since start of 
the therapy, at least n = 4.
Table 3: Secondary outcomes
→ Variation of the primary outcome (averaged pain intensity)
→ Frequency of pain attacks per day
→ Pain intensity:
▪ Pain at rest
▪ Pain attack
→ Time to symptom alleviation
→ Analgesic demand
→ Side effects of the therapy
→ Standardised pain questionnaires
▪ Neuropathic Pain questionnaire (NPI)
▪ Quality of life (SF 36)
▪ Pain Disability Index (PDI)
▪ Pain description acc. to Geissner (SES)
▪ Pain discomfort list acc. to van Zerssen
→ Quantitative sensory testing (QST):
▪ thermic sensation:
▪ cold and warm detection threshold (CDT + WDT)
▪ thermic difference threshold (TSL)
▪ cold and heat pain threshold (CPT + HPT)
▪ tactile detection threshold
▪ mechanical pain threshold
▪ mechanical pain intensity
▪ mechanical allodynia
▪ wind up phenomenon
▪ vibration threshold
▪ pressure pain threshold
→ Change of rash before and after treatment
→ Incidence of postherpetic neuralgia 6 month after treatment
→ Credibility
→ Cost effectiveness
→ Side effectsBMC Complementary and Alternative Medicine 2009, 9:31 http://www.biomedcentral.com/1472-6882/9/31
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[23]. Patients are therefore asked to evaluate whether their
satisfaction and expectations are met through a specific
questionnaire according to Vincent which is comprised of
4 items: (1) How confident do you feel that this treatment
can alleviate your complaint?; (2) How confident would
you be in recommending this treatment to a friend who
suffered from similar complaints?; (3) How logical does
this treatment seem to you?; (4) How successful do you
think this treatment would be in alleviating other com-
plaints? [24]. Patient satisfaction is measured with a 10
point visual analogue scale (VAS) at the end-point of the
study.
Data entry
Data entry is done with SPSS statistical software system
(SPSS Inc., Chicago, IL; version 15.0). Data analysis will
be done with SAS/STAT® Software (SAS Institute Inc., Cary,
NC, USA) All data entry will be carried out twice.
Discussion
To our knowledge, the ACUZoster study is the first clinical
study to investigate the effectiveness of an acupuncture
treatment for acute herpes zoster pain in direct compari-
son to a standard analgesic treatment with gabapentine
and to a sham laser acupuncture treatment in a three-
armed, randomised controlled clinical trial. Compared to
previous studies of acupuncture in the treatment of herpes
zoster, this study has a more rigorous methodology and
will include more patients.
As pain in Herpes zoster is a prevalent symptom, zoster
neuralgia figures an established model to investigate neu-
ropathic pain therapies [10]. Therefore we believe that the
expected results will not only confirm the present basic
analgesic therapy in zoster neuralgia, it will also be possi-
ble to reason by analogy on other painful neuropathic
conditions. However, depending on different age and
gender distribution, thus leading to different pain percep-
tions within the patients' cohort, we can not control each
patient's symptoms individually. We think that the bal-
anced randomisation process accounts on this source of
bias.
Inclusion and exclusion criteria were hold pragmatic in
order to facilitate screening and recruitment. Exclusion
criteria (besides standard items such as pregnancy or con-
tra indications to the study medication) are diseases inter-
fering with the patients' sensory perception. Our inclusion
and exclusion criteria are based on further trials evaluat-
ing sensations and on recommendations found in the lit-
erature [11,25,26].
Acupuncture versus gabapentine
No single treatment has been shown to be completely
effective for all sufferers of acute herpes zoster pain, and
in the practical clinical scenario combinations of analgesic
drugs are usually required to achieve partial relief of pain.
Although there is an increasingly large number of trials
that compare various analgesics to placebo, very few
directly compare single therapies for which an evidence
base exists, or address the issue of combining treatments
[27]. Current evidence is based on a small number of clin-
ical trials supporting the oral use of tricyclic antidepres-
sants, certain opioids, and gabapentinoids in PHN [10].
The pooled results for e.g. gabapentine give a number
needed to treat (50% pain reduction) of 4.39. This efficacy
is independent of the maximum applied dosage [10].
Gabapentine is one of the most commonly used analge-
sics in the treatment of neuropathic pain. Despite, adverse
effects are reported quite often. Patients suffer especially
from dizziness and sedation. The number needed to harm
for gabapentin is 4.07 for minor harm and 12.25 for
major harm [10]. That means that the number required to
treat is same as the number needed to provoke adverse
events.
Even as the use of acupuncture has been reported being
promising by smaller trials in neuralgia [28], neuropathic
pain [13,29] or postherpetic conditions [15], all these tri-
als come not up to enough evidence to recommend acu-
puncture as standard regimen.
To our knowledge, this is the first study evaluating the
effectiveness of acupuncture in a large scaled trial proofing
its non-inferiority in comparison to the commonly used
analgesic gabapentine, both in comparison to sham treat-
ment.
Control Procedure
There is a controversial discussion on the subject of con-
trol procedures for clinical acupuncture trials [24,30,31].
The use of superficial, or of deep, needle insertions at loca-
tions distant from real acupuncture points, also known as
minimal or sham acupuncture control, is not suitable to
constitute an inert placebo, as diverse non-specific physi-
ological effects of needle stimulation have been observed.
This procedure is more likely to merely evaluate needling
effects regarding the depth or the site of needle insertion.
There are various physiological antinociceptive effects
which are inevitable when using needle insertion or
related techniques. Development of so called placebo nee-
dles was an essential step in the methodology of research
on mechanisms of acupuncture [31]. However, applying
placebo needles in clinical trials implies methodological
problems e.g. artificial setting, loss of credibility in acu-
puncture experienced by patients while mechano-sensi-
tive Aβ-fibres are used, which by itself can activate pain
inhibitory systems [32,33]. In addition, all of these meth-
ods have a common problem of compromising the thera-
pist blinding.BMC Complementary and Alternative Medicine 2009, 9:31 http://www.biomedcentral.com/1472-6882/9/31
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In contrast, the choice of sham laser avoids activation of
non-specific physiological effects such as stimulation of
Aβ-fibres or C-fibres. Blinding of patients is easily
achieved. Blinding both therapist and patients has been
performed successful in a precedent trial [34], but was not
applicable in this trial. The treatment setting of laser acu-
puncture carries equal weight to needle acupuncture in
many respects e.g. attention, relaxation, and concentra-
tion on body sites distant from the affected painful area.
All of these are potential factors which play an important
role to both physicians and patients [35]. Using sham
laser allows evaluation of the efficacy of analogous nee-
dling.
A limitation is that the therapist is still familiar with the
difference of needle versus laser. In addition, technical
devices are not directly comparable to the manual skill of
acupuncture, and they are also liable to evoke different
patient belief in treatment effects [36].
Given that the resolution to this controversy remains in
doubt, the use of the sham laser methodology in this ran-
domised single blinded study design avoids these men-
tioned concerns while still providing a valid control.
Assessment of expectations is therefore still needed to
demonstrate the level of belief in the treatments support-
ing our contention [23,37].
We chose sham laser acupuncture as a control as this is
suggested to provoke only unspecific treatment effects
[37]. For the blinded patients, the credibility of this sham
procedure is enhanced by visual and acoustic signals
accompanying the red light emission, imitating a working
laser pen. The credibility assessment of the acupuncture
and sham treatment will be rated. This is in agreement
with studies prior to this investigation demonstrating very
similarly belief for both therapies [38,39]; we claim that
blinding of patients is effective and that the choice of the
sham laser acupuncture as a control procedure is ade-
quate. Patients are blinded as them is told that they will
receive either acupuncture or a laseracupuncture treat-
ment. It is mentioned that one treatment can be less effec-
tive and that sham treatments can be included. This way
we try to consider the ethical responsibility towards the
patient. The Ethics Committee at the University of
Munich, Germany approved this approach being suitable.
Conclusion
This study is the first large-scale randomised placebo-con-
trolled trial to evaluate the efficacy of acupuncture com-
pared to gabapentine and sham treatment. It can be
expected to provide valuable new information about the
clinical and physiological effects of acupuncture and
gabapentine in the treatment of acute herpes zoster pain.
The study has been designed pragmatically to ensure that
its findings can be implemented into clinical practice if
acupuncture or gabapentine are found to be effective
treatment strategies in acute herpes zoster pain.
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